Streetbeat News

Products Services

RXRX

Recursion Pharmaceuticals has received FDA clearance for its investigational new drug application for REC-1245, a potential treatment for biomarker-enriched solid tumors and lymphoma. This development could enhance Recursion's position in the biotech industry.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:02 pm

ACN

NVDA

Accenture and NVIDIA have launched a new business group to accelerate AI adoption. The initiative includes 30,000 trained professionals and AI refinery hubs in Europe, Asia, and North America.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:01 pm

J

Jacobs has secured a new five-year contract with Lincoln-sewer Management District 1 Wastewater Authority, enhancing its portfolio of digital and data-driven solutions. This partnership involves the City of Lincoln and Placer County in California.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:47 am

ATHE

Alterity Therapeutics presented multiple oral and poster presentations at the International Congress of Parkinson's Disease and Movement Disorders, highlighting their ongoing research and developments.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:40 am

XAIR

Beyond Air has entered a strategic partnership with Healthcare Links to expand access to its LungFit PH system. This collaboration aims to enhance the distribution and availability of the LungFit PH system, which is used for respiratory treatments.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:39 am

LLY

Eli Lilly announced a $4.5 billion investment to establish the Lilly Medicine Foundry, aimed at advancing manufacturing and drug development. The facility, opening in 2027, will enhance research and production capabilities, increasing Lilly's US capital commitment to over $23 billion since 2020.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:33 am

PAR

ParTech has launched the PAR POS Fall Release, introducing significant advancements in point-of-sale technology.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:32 am

VRCA

Verrica Pharmaceuticals is restructuring its sales and operating teams to cut costs by 50% while supporting YCANTH for molluscum contagiosum treatment. The company will incur a $1 million one-time restructuring charge and reduce sales territories from 80 to 35.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:31 am

BCRX

BioCryst Pharmaceuticals has started a Phase 1 trial for BCX17725, targeting Netherton Syndrome, a genetic disorder. Initial data from the trial is expected by the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:04 am

SLND

Southland Holdings, Inc. (NYSE:SLND) has secured a $70 million contract for the Winnipeg North End Sewage Treatment Plant Biosolids Facilities Upgrade project. The project is a joint venture with Aecon Group Inc. and MWH Constructors Canada Ltd., with Southland holding a 33.3% share. The contract will be added to Southland's backlog in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:04 am